Rating Change
UBS analysts reiterated a Neutral rating on CME Group Inc. (NASDAQ:CME) on July 06, 2026.
reiterateNASDAQ:CME
UBS Reiterates Neutral Rating on CME Group Inc. (CME)
Rating Change UBS analysts reiterated a Neutral rating on CME Group Inc. (NASDAQ:CME) on July 06, 2026. Market Context CME Group Inc.
Market Context
CME Group Inc. operates in the Financial Services sector. The stock currently trades at $234.76 with a market capitalization of $98.2B. The stock has declined 12.4% over the past 52 weeks.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for CME Group Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for CME Group Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 06, 2026 | UBS | Neutral | N/A |
| Jul 02, 2026 | Raymond James | Outperform | N/A |
| Jun 18, 2026 | Keefe, Bruyette & Woods | Outperform | N/A |
| Jun 11, 2026 | Rothschild & Co | Buy | N/A |
| Apr 23, 2026 | Barclays | Equal-Weight | N/A |
Related Tools: Analyst Ratings Dashboard | View CME Stock Page
Frequently Asked Questions
What does a Neutral rating mean for CME?
A Neutral rating from UBS reflects the analyst's outlook on CME Group Inc. (NASDAQ:CME). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CME forecast page.
